ZA948285B - 16-Substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors - Google Patents

16-Substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors

Info

Publication number
ZA948285B
ZA948285B ZA948205A ZA948205A ZA948285B ZA 948285 B ZA948285 B ZA 948285B ZA 948205 A ZA948205 A ZA 948205A ZA 948205 A ZA948205 A ZA 948205A ZA 948285 B ZA948285 B ZA 948285B
Authority
ZA
South Africa
Prior art keywords
inhibitors
androstane
aza
reductase
alpha
Prior art date
Application number
ZA948205A
Other languages
English (en)
Inventor
Philippe L Durette
William K Hagmann
Thomas J Lanza Jr
Soumya P Sahoo
Gary H Rasmusson
Richard L Tolman
Derek Von Langen
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA948285B publication Critical patent/ZA948285B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA948205A 1993-10-21 1994-10-21 16-Substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors ZA948285B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14115393A 1993-10-21 1993-10-21

Publications (1)

Publication Number Publication Date
ZA948285B true ZA948285B (en) 1995-06-19

Family

ID=22494410

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA948205A ZA948285B (en) 1993-10-21 1994-10-21 16-Substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors

Country Status (29)

Country Link
US (4) US5739137A (de)
EP (1) EP0724592B1 (de)
JP (1) JP2862376B2 (de)
KR (1) KR100363994B1 (de)
CN (1) CN1058499C (de)
AT (1) ATE175420T1 (de)
BG (1) BG61978B1 (de)
BR (2) BR9407866A (de)
CA (1) CA2173863C (de)
CY (1) CY2136B1 (de)
CZ (1) CZ292614B6 (de)
DE (1) DE69415824T2 (de)
DK (1) DK0724592T3 (de)
ES (1) ES2125495T3 (de)
FI (1) FI961697A0 (de)
HK (1) HK1009047A1 (de)
HU (1) HUT74613A (de)
IL (1) IL111357A (de)
LV (2) LV11622B (de)
NO (1) NO308037B1 (de)
NZ (1) NZ275293A (de)
PL (1) PL179611B1 (de)
RO (1) RO116197B1 (de)
RU (1) RU2142956C1 (de)
SK (1) SK281645B6 (de)
TW (1) TW413682B (de)
UA (1) UA44257C2 (de)
WO (1) WO1995011254A1 (de)
ZA (1) ZA948285B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547957A (en) 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
KR100363994B1 (ko) * 1993-10-21 2003-04-10 머크 앤드 캄파니 인코포레이티드 16-치환된-4-아자-안드로스탄5-알파-리덕타제아이소자임1억제제
US5470976A (en) * 1994-09-07 1995-11-28 Merck & Co., Inc. Process for the stereoselective reduction of steroid enelactams
CA2199979A1 (en) * 1994-10-21 1996-05-02 Joanne Waldstreicher Combination method for acne treatment
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5886005A (en) * 1995-01-17 1999-03-23 Merck & Co., Inc. 4-Aza-19-norandrostane derivatives
AU704933B2 (en) * 1995-10-19 1999-05-06 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5872126A (en) * 1996-09-06 1999-02-16 Merck & Co., Inc. Methods and compositions for treating preterm labor
US5945412A (en) * 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
US5935968A (en) 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
WO1998041509A1 (en) * 1997-03-17 1998-09-24 Merck & Co., Inc. Methods and compositions for treating polycystic ovary syndrome
JP2001521000A (ja) * 1997-10-28 2001-11-06 メルク エンド カムパニー インコーポレーテッド 誘発性急性閉尿の予防
US6187925B1 (en) * 1997-12-23 2001-02-13 Merck & Co., Inc. Intermediates and process for the synthesis of azasteroids
AR016257A1 (es) * 1998-05-14 2001-06-20 Merck & Co Inc Proceso para la sintesis estereoselectiva de ariloxi-4-aza-5alfa-androstan-3-onas, 16 alfa y 16 beta-sustituidas e insustituidas, e intermediariosobtenidos en dicho proceso.
WO1999058550A1 (en) * 1998-05-14 1999-11-18 Merck & Co., Inc. 7beta-methyl-16beta-((4-methylsulfonyl)-phenoxy)-4-aza-5alpha-androst-1-en-3-one as a 5-alpha-reductase isozyme 1 inhibitor
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
AU754604B2 (en) * 1998-07-29 2002-11-21 Merck & Co., Inc. Tricyclic compounds
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
EP1734963A4 (de) * 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
EP1865955A4 (de) * 2005-03-25 2009-04-15 Merck & Co Inc Verfahren zur behandlung von männern mit testosteronergänzung und alpha-reduktase-hemmer
US20060241696A1 (en) * 2005-04-26 2006-10-26 Stjepan Krco Method of limiting hair loss and promoting hair growth
FR2910002B1 (fr) * 2006-12-13 2009-01-30 Sanofi Aventis Sa Nouveau procede pour l'obtention diastereoselective d'une amine primaire chirale sur un steroide
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic
TWI593411B (zh) 2013-04-30 2017-08-01 徐懷山 組合物於製備抑制雄性素受體有關之功能及治療雄性素 受體相關之疾病的藥物之用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
US5151429A (en) * 1984-02-27 1992-09-29 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
EP0285382B1 (de) * 1987-04-03 1994-04-13 Merck & Co. Inc. Behandlung von androgener Alopecia mit 17-bêta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen
US5084574A (en) * 1988-04-18 1992-01-28 Merck & Co., Inc. Dehydrogenation process
US5116983A (en) * 1988-04-18 1992-05-26 Merck & Co., Inc. Dehydrogenation process intermediates
CA2084798A1 (en) * 1991-12-17 1993-06-18 Glenn J. Gormley Method of preventing prostatic carcinoma with 17beta -acyl-4-aza-5.- androst-1-ene-3-ones
GB2264494A (en) * 1992-02-25 1993-09-01 Merck & Co Inc 17b-n-monosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-1-en-3-one testosterone-5-alpha reductase inhibitors
US5215894A (en) * 1992-02-25 1993-06-01 Merck & Co., Inc. Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors
HUT71484A (en) * 1992-05-20 1995-11-28 Merck & Co Inc Process for producing of 7beta-substituted-4-aza-5alpha-cholestan-ones as 5-alpha-reductase inhibitors and pharmaceuticals compositions containing them
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
EP0641209A4 (de) * 1992-05-20 1995-08-23 Merck & Co Inc Neue 17-ester-, amid- und ketonderivate von 3-oxo-4-azasteroiden als 5-alpha-reduktaseinhibitoren.
KR950701527A (ko) * 1992-05-21 1995-04-28 라브리 페르낭 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
GB9216329D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5380728A (en) * 1993-02-10 1995-01-10 Merck & Co., Inc. Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a
US5407944A (en) * 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
KR100363994B1 (ko) * 1993-10-21 2003-04-10 머크 앤드 캄파니 인코포레이티드 16-치환된-4-아자-안드로스탄5-알파-리덕타제아이소자임1억제제
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5512555A (en) * 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents

Also Published As

Publication number Publication date
NO961575D0 (no) 1996-04-19
TW413682B (en) 2000-12-01
DE69415824T2 (de) 1999-08-05
US5910497A (en) 1999-06-08
KR960705839A (ko) 1996-11-08
LV12316A (lv) 1999-07-20
DK0724592T3 (da) 1999-08-30
HUT74613A (en) 1997-01-28
US5739137A (en) 1998-04-14
EP0724592B1 (de) 1999-01-07
US5719158A (en) 1998-02-17
WO1995011254A1 (en) 1995-04-27
AU680063B2 (en) 1997-07-17
ATE175420T1 (de) 1999-01-15
RO116197B1 (ro) 2000-11-30
BR9407866A (pt) 1996-10-29
EP0724592A1 (de) 1996-08-07
HU9601037D0 (en) 1996-06-28
US6204273B1 (en) 2001-03-20
CN1136318A (zh) 1996-11-20
IL111357A0 (en) 1994-12-29
CZ122896A3 (en) 1997-01-15
JPH09511213A (ja) 1997-11-11
CY2136B1 (en) 2002-06-21
BG100516A (en) 1996-11-29
NO308037B1 (no) 2000-07-10
CA2173863C (en) 2003-05-13
CN1058499C (zh) 2000-11-15
BR1100217A (pt) 1999-11-09
FI961697A (fi) 1996-04-18
LV11622A (lv) 1996-12-20
SK49696A3 (en) 1996-10-02
FI961697A0 (fi) 1996-04-18
IL111357A (en) 2001-01-28
PL179611B1 (pl) 2000-10-31
PL314039A1 (en) 1996-08-05
KR100363994B1 (ko) 2003-04-10
LV11622B (en) 1997-06-20
NZ275293A (en) 1998-02-26
NO961575L (no) 1996-04-19
RU2142956C1 (ru) 1999-12-20
AU8086194A (en) 1995-05-08
HK1009047A1 (en) 1999-05-21
ES2125495T3 (es) 1999-03-01
LV12316B (en) 1999-11-20
CZ292614B6 (cs) 2003-11-12
UA44257C2 (uk) 2002-02-15
JP2862376B2 (ja) 1999-03-03
SK281645B6 (sk) 2001-06-11
BG61978B1 (bg) 1998-11-30
CA2173863A1 (en) 1995-04-27
DE69415824D1 (de) 1999-02-18

Similar Documents

Publication Publication Date Title
HK1009047A1 (en) 16-Substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
GEP20094660B (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases
EP0641208A4 (de) 4-azasteroide als 5-alpha-reduktase.
ATE143942T1 (de) Carbonsäurederivate als 5-alpha-reduktase- inhibitor
MY123960A (en) Method of treating androgenic alopecia with 5- alpha reductase inhibitors.
EP0748221A4 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
HU9600976D0 (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors
EP0649431A4 (en) 17-amino substituted 4-azasteroid 5-g(a)-reductase inhibitors.
EP0756481A4 (de) 17 beta-aryl-4-aza-steroidderivate
LV12721A (lv) 17-beta-carboxanilides of 4-aza-5-alpha-androstan-3-ones as 5-alpha-reductase inhibitors
ES2160842T3 (es) Derivados de esteroides 17-alquil-4-aza-7-sustituidos.
YU12295A (sh) 16-supstituisani-4-aza-androstani inhibitori 5-alfa-reduktaze izozima 1